R3 Vascular key facts
- Developer of medical metallic stents devices designed to treat peripheral arterial diseases.
- R3 Vascular’s last known valuation is $145.0M.
- It has raised $105.6M across 2 recorded rounds; the latest was Later Stage VC ($72.5M) in Apr 2024.
- Notable investors include Deerfield Management, 415 Capital, M&L Group, MedFocus, Philips Ventures — 6 tracked in total.
- R3 Vascular has filed 2 Form Ds with the SEC since 2020, most recently Sep 2024 ($72.5M sold to 34 investors).
- Status: Privately Held (backing).
Who backs R3 Vascular
6- ·Watch R3 Vascular: the Monday email on marks, rounds and moves
R3 Vascular funding rounds
2 roundsR3 Vascular valuation
R3 Vascular's last known valuation is $145 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
How much has R3 Vascular raised?
R3 Vascular has raised $106 million in total; 2 of its rounds are on record. The largest on record was a $72.5 million later-stage round in Apr 2024.
R3 Vascular has filed 2 Form Ds with the SEC since 2020, most recently in Sep 2024 ($72.5 million sold to 34 investors).
R3 Vascular investors
6 investors are on record for R3 Vascular, including Deerfield Management, 415 Capital, M&L Group and MedFocus. The later-stage round in Apr 2024 drew 34 investors.
About R3 Vascular
Developer of medical metallic stents devices designed to treat peripheral arterial diseases. The company offers bioresorbable vascular scaffolds, and BVS technology with a sirolimus coating which has anti-inflammatory properties, enabling physicians to treat peripheral arterial disease below the knee.
- Sector
- Healthcare
- HQ
- Mountain View, CA, United States
- Founded
- 2019
- Employees
- 22
- Website
- r3vascular.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
R3 Vascular’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.